Abstract We hypothesized that blood levels of γ-aminobutyric acid (GABA) and γ-hydroxybutyric acid (GHB), biomarkers of succinic semialdehyde dehydrogenase deficiency (SSADHD), would correlate with age. GABA and GHB were quantified in plasma and red blood cells (RBCs) from 18 patients (age range 5-41 years; median 8). Both metabolites negatively correlated with age (P < 0.05). Plasma and RBC GHB declined with age, reaching a nadir and approximate steady state by 10 years. Declining plasma GABA achieved this approximate steady state at 30-40 years of age. These biomarker relationships may reflect further GABA-and GHB-ergic neurotransmission imbalances that correlate with the onset of adolescent/adulthood neuropsychiatric morbidity and epilepsy in SSADHD.
Introduction
A rare disorder of γ-aminobutyric acid (GABA) catabolism, succinic semialdehyde dehydrogenase deficiency (SSADHD), has been reported in ∼200 patients worldwide (Malaspina et al. 2016 ). The phenotype is nonspecific, with developmental delay, hypotonia, absence of formulated speech, and the onset of neuropsychiatric morbidity (obsession-compulsion, attention deficit, oppositional defiant disorders) in adolescence to adulthood. Autism spectrum disorder is frequently considered in the differential diagnosis (Malaspina et al. 2016; Parviz et al. 2014) . Detection of SSADHD requires measurement of γ-hydroxybutyrate (GHB; the biochemical hallmark) in peripheral biofluids, although GABA is also elevated in cerebral spinal fluid (CSF) (Gibson et al. 1995 (Gibson et al. , 2003 . Both compounds have either neurotransmitter, or neuromodulatory, roles in the central nervous system (CNS) (Maitre et al. 2016 ; Fig. 1 ).
The natural history of SSADHD remains unknown, and a longitudinal study that may define it is lacking. Nonetheless, anecdotal evaluation of reported cases has highlighted the onset of neuropsychiatric morbidity in adolescence and adulthood (Parviz et al. 2014; Pearl et al. 2014) . Moreover, Knerr and coworkers identified a more severe disease course in a subset of patients in whom the epileptic disorder appears more severe (Knerr et al. 2007) . Importantly, some patients expired with sudden unexplained death in epilepsy (SUDEP) in adulthood (Lapalme-Remis et al. 2015; Knerr et al. 2010; Gibson and Pearl, unpublished) . To explore the natural history of SSADHD, we sought to identify biomarkers in physiological fluids that may provide pathophysiological insight into disease evolution. Here, we examine the levels of both GABA and GHB in urine, plasma, and RBCs to address potential age-dependent correlations. Our working hypothesis centered on the prediction that blood levels of both biomarkers would reflect biomarker disturbances in CNS, providing insight into disease progression and evolution.
Methods
Whole-blood and urine were obtained from patients with SSADHD (age range 5-41 years; median 8), obligate heterozygotes (parents), and control individuals with informed consent (IRB 12678). For the physiological fluids evaluated, the number of control individuals were eight (plasma total GABA and RBC GHB), 11 (plasma GHB), and 13 (urine GHB). Control individuals were not age matched to patients, although we speculate that the age range of both cohorts overlapped. The majority of controls were adults, although some were siblings of patients (children and adolescents) whose genetic status was unknown. For control individuals, gender status was identified only for seven and age only for four, making correlative analyses between metabolic findings and age/gender challenging. Clinical details were not available on patients at the time of sample shipment, and to our knowledge, none of the patients was concurrently receiving vigabatrin or other antiepileptic that may have artefactually elevated plasma total GABA, as is the case for GABA in CSF of patients receiving vigabatrin (Gibson et al. 1995; Casado et al. 2014 ).
Blood samples, upon receipt in the laboratory, were fractionated into plasma, mixed polymorphonuclear cells, and packed RBCs. Although GABA levels have been effectively quantified in platelets isolated from whole blood (Kowa et al. 1992) , we opted for isolation of plasma, since an objective was to determine whether total GABA levels might be elevated in this compartment and potentially inform GABA concentrations in whole bloodspots for eventual newborn screening of SSADHD. Moreover, since we recently demonstrated that both GHB and GABA are significantly elevated in brain and peripheral organs (kidney, liver) of SSADH-deficient mice (Vogel et al., in revision), we assume that peripheral GABA metabolism mimics the pathway of metabolism shown in the brain. The latter underscores the utility of measuring these biomarkers in peripheral tissues (plasma, RBCs) as a surrogate for brain, or even CSF, measurements. Total GABA in plasma and GHB in urine, plasma, and RBC extracts were quantified as described (Kok et al. 1993; Gibson et al. 1990 ). Statistical analysis was performed using GraphPad Prizm 6.0 (San Diego, CA, USA).
Results
Total plasma GABA values for controls were 2.16 ± 0.19 μmol/L [mean ± standard error (SEM) n = 8; median 2.06, range 1.7-3.32], for obligate heterozygotes (parents) 2.16 ± 0.12 (n = 5; median 2.24, range 1.86-2.42), and for SSADHD 4.16 ± 0.25 (n = 16, median 4.04, range 2.14-5.52; p < 0.001 compared with control and obligate heterozygotes, two tailed t test)] (Fig. 2a) . When stratified for patient age, total plasma GABA showed a significant negative correlation ( Fig. 2b ; P = 0.0082, Spearman coefficient, 10 male and 6 female patients). A negative correlation was also observed when evaluating patients only (P = 0.0007) (Fig. 3a, d) .
Plasma GHB values for controls were 1.14 ± 0.23 μmol/L (mean ± SEM, n = 11; median 0.8, range 0.5-2.9), for obligate heterozygotes 1.14 ± 0.23 (n = 5; median 1.1, range 0.5-1.9), and for SSADHD 179.1 ± 44.1 (n = 18, median 67.6, range 25.5-533; P < 0.05 compared with both groups, two-tailed t test) (Fig. 2d) . Plasma GHB showed a significant negative correlation with age ( Fig. 2e ; P = 0.0017, Spearman coefficient, 12 male and 6 female patients). A negative correlation was also observed when evaluating male patients only (P = 0.0014) (Fig. 3b, e) . RBC GHB levels for controls were 4.19 ± 0.45 μmol/L (mean ± SEM, n = 8; median 3.9, range 2.8-6.4), for obligate heterozygotes 5.56 ± 1.05 (n = 5; median 5.4, range 2.9-9.3), and for SSADHD, 58.0 ± 11.5 (n = 16, median 54.2, range 9.6-139; P < 0.05 compared with both groups, two-tailed t test) (Fig. 2g) . RBC GHB showed a significant negative correlation ( Fig. 2h ; P = 0.0214, Spearman coefficient, 12 male and 6 female patients). A negative correlation was also observed when evaluating male patients only Fig. 1 GABA metabolism: site of block in patients with SSADHD is indicated by the filled black box. GABA γ-aminobutyric acid, GABA-T GABA-transaminase, SSADH succinic semialdehyde dehydrogenase, SSA succinic semialdehyde, GHB γ-hydroxybutyric acid.
(P = 0.0078), but not with female patients (Fig. 3c, f) . Urine samples were also available from 18 patients, although age characteristics were known only for eight patients. Urine GHB levels for controls were 1.68 ± 0.77 mmol/mol creatinine (mean ± SEM, n = 13; median 0.4, range 0.12-10.1), for obligate heterozygotes 1.84 ± 1.37 (n = 14; median 0.4, range 0.10-19.6), and for SSADHD 158.5 ± 27.0 (n = 18, median 153, range 26.8-514; P < 0.0001 compared with both groups, two-tailed t test). There was no correlation between urine GHB concentration and age (data not shown).
Correlations between plasma total GABA and GHB revealed a profile that attained a plateau at total GABA levels of ∼5 μmol/L and GHB concentrations ∼300 μmol/L ( Fig. 2c ; P < 0.0001). Similar results were seen for plasma total GABA (∼5 μmol/L) and RBC GHB of ∼ 65 μmol/L (P = 0.0006; Fig. 2i) . The relationship between plasma and RBC GHB was linear ( Fig. 2f ; P < 0.0001, Pearson coefficient). For patients, there was no significant difference with respect to gender for any of the metabolites evaluated (Fig. 4a-c) . Information on gender and age characteristics for the control cohort were limited (Fig. 4) . For the few control individuals for whom gender was known, plasma and RBC GHB levels were not significantly different (Figs. 4e, f) , but only two individuals were identified as male. For plasma total GABA, mean value in males was significantly higher compared with females ( Fig. 4a) , but for males, the control cohort contained only two individuals.
Discussion
Total GABA and GHB in plasma and RBC extracts revealed a significant negative correlation with age (Fig. 2b, e, h ). Low plasma GABA has previously been associated with neuropsychiatric morbidity. Plasma GABA was negatively correlated with age and aggressiveness in individuals with a first-degree relative with primary unipolar depressive disorder (Bjork et al. 2001) , positively correlated with depression and apathy and negatively correlated with age in severe Alzheimer's disease (Lanctot et al. 2007 ). The phenotype of SSADHD often includes neuropsychiatric morbidity in adolescence to adulthood, including attention deficit-hyperactivity, oppositionaldefiant, and obsessive-compulsive disorders (Malaspina et al. 2016) . We found tapering of levels for GHB at about 10 years of age, whereas this same tapering for plasma total GABA was not evident until at least 30 years of age. The lowered levels of GHB may track with the onset of neuropsychiatric morbidity in patients (Parviz et al. 2014) , but further studies are needed to verify this hypothesis. Moreover, we know that a subset of patients with SSADHD has a more severe phenotype, featuring adult-onset epilepsy (Parviz et al. 2014) , and there have been instances of SUDEP in adulthood (Lapalme-Remis et al. 2015; Knerr et al. 2010; Gibson and Pearl, unpublished observation) . Previously, Casado and coworkers (2014) documented that GABA levels in CSF from 55 pediatric controls showed a progressive increase with age. We were unable to assess this age-related parameter in our control cohort since information on age characteristics was limited.
Several publications have highlighted alterations in GABAergic neurotransmission in SSADHD (Pearl et al. 2009; Reis et al. 2012; Buzzi et al. 2006) , both in the orthologue mouse model and in patients, and it may be reasonable to assume that high levels of GABA and GHB during ontogeny induces an altered balance between GABAergic/ GHBergic neurotransmission with that of excitatory glutamatergic neurotransmission (Jansen et al. 2008; Vogel et al. 2016; Talaei et al. 2016 ). Our prediction is that as levels of GABA and GHB fall with age, this balance is likely disrupted and correlates with neuropsychiatric morbidity in patients. A comprehensive longitudinal evaluation of SSADHD, correlating brain and blood levels of GABA and GHB with age and phenotype, could address this issue.
Our study represents the first identification of elevated total plasma GABA of patients with SSADHD. This is relevant for several reasons. First, appropriate testing for GHB in order to achieve accurate diagnosis may be overlooked due to the nonspecific neurological phenotype (Lapalme-Remis et al. 2015) . Additionally, clinical trials for SSADHD are either underway or completed www.clinicaltrials.gov) , and a therapeutic pipeline is under development using the corresponding murine model (Malaspina et al. 2016) . Accordingly, early detection of the disease, preferably through newborn screening, would be desirable. This may be even more compelling, since many patients with SSADHD are not diagnosed until at least 2 years of age, such that the early course of the disease is largely unknown (Malaspina et al. 2016) . Thus, early detection via newborn screening could begin to outline the early natural history of SSADHD while informing symptomatic management and providing families with important predictive information. Forni and colleagues (2013) presented methodology for quantitation of GHB in bloodspots from newborns. The method, however, is not readily interfaced to current newborn screening platforms, which quantifies nitrogenous species (amino acids, L-carnitine analogs; Therrell et al. 2015) . Accordingly, plasma total GABA may provide a more rapid path to newborn screening of SSADHD, although it is likely that other neurological conditions could result in elevated GABA levels in bloodspots from newborns (e.g., neuropsychiatric conditions, GABAtransaminase deficiency, etc.).
Since the discovery of SSADHD in the early 1980s (Jakobs et al. 1981) , GHB has been employed as the biochemical hallmark of the disease and its identification in physiological fluids has enabled accurate diagnosis. Later studies on SSADHD also revealed elevations of GABA in the CNS, using both CSF analyses and magnetic resonance spectroscopy (Gibson et al. 1995 (Gibson et al. , 2003 Novotny et al. 2003 ). We now demonstrate and report here for the first time that measurement of GABA and GHB in peripheral biofluids may provide information about the natural history of SSADHD, thereby providing a mechanism for predicting sequence and timing of symptom onset and development of complications. . Statistical analysis employed a two-way t test, and no significant differences were observed for any metabolite. d-f Gender comparisons within the control cohort. Gender characteristics were available only for a limited number of individuals. For total plasma γ-aminobutyric acid (GABA), a significantly higher mean value was observed in males vs. females (d; two-way t test), but only two males populated this group
